journal article·2012-06Open access

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

Vikash P. Chauhan, Triantafyllos Stylianopoulos, John D. Martin, Zoran Popović, Ou Chen, Walid S. Kamoun, Moungi G. Bawendi, Dai Fukumura, Rakesh K. Jain

Nature Nanotechnology· Volume 7· Issue 6

Abstract

The blood vessels of cancerous tumours are leaky and poorly organized. This can increase the interstitial fluid pressure inside tumours and reduce blood supply to them, which impairs drug delivery. Anti-angiogenic therapies--which 'normalize' the abnormal blood vessels in tumours by making them less leaky--have been shown to improve the delivery and effectiveness of chemotherapeutics with low molecular weights, but it remains unclear whether normalizing tumour vessels can improve the delivery of nanomedicines. Here, we show that repairing the abnormal vessels in mammary tumours, by blocking vascular endothelial growth factor receptor-2, improves the delivery of smaller nanoparticles (diameter, 12 nm) while hindering the delivery of larger nanoparticles (diameter, 125 nm). Using a mathematical model, we show that reducing the sizes of pores in the walls of vessels through normalization decreases the interstitial fluid pressure in tumours, thus allowing small nanoparticles to enter them more rapidly. However, increased steric and hydrodynamic hindrances, also associated with smaller pores, make it more difficult for large nanoparticles to enter tumours. Our results further suggest that smaller (∼12 nm) nanomedicines are ideal for cancer therapy due to their superior tumour penetration.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Angiogenesis and VEGF in Cancer · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998).10.1073/pnas.95.8.4607 ↗
2. Nagy, J. A., Dvorak, A. M. & Dvorak, H. F. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2, 251–275 (2007).10.1146/annurev.pathol.2.010506.134925 ↗
3. Yuan, F. et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352–3356 (1994).
4. Baish, J. W. et al. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc. Natl Acad. Sci. USA 108, 1799–1803 (2011).10.1073/pnas.1018154108 ↗
5. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298–307 (2011).10.1038/nature10144 ↗
6. Gazit, Y., Berk, D. A., Leunig, M., Baxter, L. T. & Jain, R. K. Scale-invariant behavior and vascular network formation in normal and tumor tissue. Phys. Rev. Lett. 75, 2428–2431 (1995).10.1103/PhysRevLett.75.2428 ↗
7. Nagy, J. A., Chang, S. H., Dvorak, A. M. & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100, 865–869 (2009).10.1038/sj.bjc.6604929 ↗
8. Chauhan, V. P., Stylianopoulos, T., Boucher, Y. & Jain, R. K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281–298 (2011).10.1146/annurev-chembioeng-061010-114300 ↗
9. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).10.1126/science.1104819 ↗
10. Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071–1121 (2011).10.1152/physrev.00038.2010 ↗
11. Jain, R. K. & Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022–7032 (1988).
12. Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004).10.1158/0008-5472.CAN-04-0074 ↗
13. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553–563 (2004).
14. Nakahara, T., Norberg, S. M., Shalinsky, D. R., Hu-Lowe, D. D. & McDonald, D. M. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 66, 1434–1445 (2006).10.1158/0008-5472.CAN-05-0923 ↗
15. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145–147 (2004).10.1038/nm988 ↗
16. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).10.1016/j.ccr.2006.11.021 ↗
17. Sorensen, A. G. et al. Increased survival of glioblastoma patients who respond to anti-angiogenic therapy with elevated blood perfusion. Cancer Res. 72, 402–407 (2012).10.1158/0008-5472.CAN-11-2464 ↗
18. Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nature Rev. Clin. Oncol. 7, 653–664 (2010).10.1038/nrclinonc.2010.139 ↗
19. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2, 751–760 (2007).10.1038/nnano.2007.387 ↗
20. Popovic, Z. et al. A nanoparticle size series for in vivo fluorescence imaging. Angew. Chem. Int. Ed. 49, 8649–8652 (2010).10.1002/anie.201003142 ↗
21. Chauhan, V. P. et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew. Chem. Int. Ed. 50, 11417–11420 (2011).10.1002/anie.201104449 ↗
22. Gazit, Y. et al. Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation 4, 395–402 (1997).10.3109/10739689709146803 ↗
23. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363–1380 (2000).10.1016/S0002-9440(10)65006-7 ↗
24. Baish, J. W., Netti, P. A. & Jain, R. K. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc. Res. 53, 128–141 (1997).10.1006/mvre.1996.2005 ↗
25. Pozrikidis, C. & Farrow, D. A. A model of fluid flow in solid tumors. Ann. Biomed. Eng. 31, 181–194 (2003).10.1114/1.1540103 ↗
26. Bungay, P. M. & Brenner, H. The motion of a closely-fitting sphere in a fluid-filled tube. Int. J. Multiphase Flow 1, 25–56 (1973).10.1016/0301-9322(73)90003-7 ↗
27. Deen, W. M. Hindered transport of large molecules in liquid-filled pores. AIChE J. 33, 1409–1425 (1987).10.1002/aic.690330902 ↗
28. Sarin, H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes. Res. 2, 14 (2010).10.1186/2040-2384-2-14 ↗
29. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46, 6387–6392 (1986).
30. Ruoslahti, E., Bhatia, S. N. & Sailor, M. J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188, 759–768 (2010).10.1083/jcb.200910104 ↗